Epysqli Prices, Coupons, Copay Cards & Patient Assistance
Epysqli (eculizumab) is a member of the selective immunosuppressants drug class and is commonly used for Hemolytic Uremic Syndrome, and Paroxysmal Nocturnal Hemoglobinuria.
The cost for Epysqli (aagh 10 mg/mL) intravenous solution is around $4,884 for a supply of 30 milliliters, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
Epysqli prices
Intravenous Solution
aagh 10 mg/mL
Epysqli intravenous solution
from $4,884.30
for 30 milliliters
Quantity | Per unit | Price |
---|---|---|
30 milliliters | $162.81 | $4,884.30 |
Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
Drugs.com Printable Discount Card
The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.
Print Free Discount CardNote: This is a drug discount program, not an insurance plan. Valid at all major chains including Walgreens, Target, WalMart Pharmacy, Duane Reade and 65,000 pharmacies nationwide.
Epysqli Coupons, Copay Cards and Rebates
Epysqli offers may take the form of printable coupons, rebates, savings or copay cards, trial offers, or free samples. Certain offers may be printable from a website while others may require registration, completing a questionnaire, or obtaining a sample from a medical professional.
No manufacturer promotions could be found for this medication.
Patient Assistance & Copay Programs for Epysqli
Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. Eligibility requirements for each program may vary.
Provider: Patient Access Network Foundation (PAN)
Eligibility requirements:- *See Additional Information section below
- Between 400-500% of FPL
- FDA Approved Diagnosis - See Program Website for Details
- Must reside and receive treatment in US
- *Patients must have health insurance and their insurance must cover the qualifying medication for which they seek assistance. Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly. Note: All new enrollment is now done electronically or over the phone. Contact program for details.
- Epysqli (eculizumab-aagh) Injection; IV
More information please phone: 866-316-7263 Visit Website
Disclaimer: Medication pricing is sourced from a variety of providers. Pricing may vary significantly due to several factors including brand or generic status, insurance coverage, pharmacy choice, location, and manufacturer pricing policies. Prices are subject to change. For the most accurate and up-to-date information, always consult directly with your pharmacy or healthcare provider.
See also:
Ultomiris
Ultomiris (ravulizumab-cwvz) is used for the treatment of myasthenia gravis, paroxysmal nocturnal ...
Fabhalta
Fabhalta is used to treat paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A ...
Empaveli
Empaveli (pegcetacoplan) is an immunosuppressant that is given by subcutaneous (under the skin) ...
Soliris
Soliris infusion is used to treat adults with paroxysmal nocturnal hemoglobinuria (PNH), adults and ...
PiaSky
PiaSky (crovalimab-akkz) may be used to treat paroxysmal nocturnal hemoglobinuria (PNH) in adults ...
Bkemv
Bkemv (eculizumab-aeeb) is an interchangeable biosimilar to Soliris which may be used to treat ...
Danicopan
Danicopan systemic is used for paroxysmal nocturnal hemoglobinuria
Iptacopan
Iptacopan is an oral capsule used to treat paroxysmal nocturnal hemoglobinuria (PNH) or to reduce ...
Pegcetacoplan
Pegcetacoplan (brand name Empaveli) is a twice-weekly, injectable medicine that may be used to ...
Ravulizumab
Ravulizumab-cwvz is used to treat myasthenia gravis (gMG), hemolytic uremic syndrome (aHUS) ...
More about Epysqli (eculizumab)
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: selective immunosuppressants
- Breastfeeding